{
    "name": "olmesartan/amlodipine/hydrochlorothiazide",
    "comment": "Rx",
    "other_names": [
        "Tribenzor"
    ],
    "classes": [
        "ARB/CCB/Diuretic Combos"
    ],
    "source": "https://reference.medscape.com/drug/tribenzor-olmesartan-amlodipine-hydrochlorothiazide-999588",
    "pregnancy": {
        "common": [
            "Therapy can cause fetal harm in pregnant women; use of drugs that act on renin-angiotensin system during second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death",
            "Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in first trimester have not distinguished drugs affecting renin-angiotensin system from other antihypertensive agents",
            "When pregnancy is detected, discontinue therapy as soon as possible; consider alternative antihypertensive therapy during pregnancy",
            "Hypertension in pregnancy increases maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (eg, need for cesarean section and post-partum hemorrhage); hypertension increases fetal risk for intrauterine growth restriction and intrauterine death; pregnant women with hypertension should be carefully monitored and managed accordingly.",
            "Oligohydramnios in pregnant women who use drugs affecting renin-angiotensin system in second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death",
            "Perform serial ultrasound examinations to assess intra-amniotic environment; fetal testing may be appropriate, based on week of gestation; patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.",
            "Closely observe infants with histories of in utero exposure to olmesartan for hypotension, oliguria, and hyperkalemia; in neonates with a history of in utero exposure to olmesartan",
            "If oliguria or hypotension occur, utilize measures to maintain adequate blood pressure and renal perfusion; exchange transfusions or dialysis may be required as a means of reversing hypotension and supporting renal function",
            "Thiazides cross placental barrier and appear in cord blood; adverse reactions include fetal or neonatal jaundice and thrombocytopenia"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is limited information regarding the presence of drug in human milk, effects on breastfed infant, or on milk production; amlodipine is present in human milk; olmesartan is present in rat milk",
            "Because of potential for adverse effects on nursing infant, advise a nursing woman that breastfeeding is not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to any drug component or sulfonamide-derived drug",
                "Anuria",
                "Concomitant use with aliskiren in patients with diabetes mellitus",
                "Pregnancy (2nd and 3rd trimesters): significant risk of fetal/neonatal morbidity and mortality"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Angioedema, severe CHF, surgery/anesthesia, volume depletion (consider lower dose)",
                "Discontinue STAT if pregnant: potential risk of congenital malformations (see Black Box Warnings)",
                "Antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient",
                "Risk of hypotension in patients with severe aortic stenosis; if hypotension does occur, place patient in supine position and, if necessary, give an intravenous infusion of normal saline; a transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once blood pressure has stabilized",
                "Increased angina or myocardial infarction particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction upon starting calcium channel blocker therapy or at time of dosage increase; mechanism of this effect has not been elucidated",
                "Risk of hyperkalemia",
                "Dual blockade of the renin-angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy; closely monitor blood pressure",
                "Intestinal problems (ie, sprue-like enteropathy) reported with olmesartan; severe, chronic diarrhea with substantial weight loss reported in patients taking olmesartan months to years after drug initiation; intestinal biopsies of patients often demonstrated villous atrophy; if a patient develops these symptoms during treatment with olmesartan, exclude other etiologies; consider discontinuation of therapy in cases where no other etiology identified",
                "Photosensitivity may occur; instruct patients to protect skin from sun and undergo regular skin cancer screening",
                "Avoid with severe renal impairment (<30 mL/min)",
                "Withhold/discontinue if progressive renal impairment occurs; in patients whose renal function may depend upon activity of renin-angiotensin-aldosterone system (eg, patients with severe congestive heart failure), treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria or progressive azotemia and (rarely) with acute renal failure and/or death; similar effects may occur in patients receiving this therapy due to olmesartan medoxomil component",
                "Thiazides: use with caution with mild/moderate liver impairment or progressive liver disease; avoid in patients with severe liver impairment",
                "Monitor for fluid/electrolyte imbalance",
                "Use caution in heart failure, severe aortic stenosis (amlodipine), hepatic impairment, renal artery stenosis, or hypertrophic cardiomyopathy",
                "Thiazide diuretics may exacerbate or activate SLE",
                "Acute transient myopia and acute angle-closure glaucoma reported, particularly with history of sulfonamide or penicillin allergy (hydrochlorothiazide is a sulfonamide); symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation; untreated acute angle-closure glaucoma can lead to permanent vision loss; primary treatment is to discontinue hydrochlorothiazide as rapidly as possible; prompt medical or surgical treatments may need to be considered if intraocular pressure remains uncontrolled; risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy",
                "Caution in aortic mitral stenosis, hepatic impairment, hypercholesterolemia, hypercalcemia, parathyroid disease, pre-existing renal insufficiency, systemic lupus erythematosus, bilateral renal artery stenosis or anuria",
                "Thiazide diuretics reported to cause exacerbation or activation of systemic lupus erythematosus",
                "Increased incidence of impaired renal function reported in subjects receiving triple drug combination therapy compared to subjects receiving dual combination therapy of olmesartan medoxomil and amlodipine, olmesartan medoxomil and hydrochlorothiazide or amlodipine and hydrochlorothiazide; if progressive renal impairment becomes evident consider withholding or discontinuing therapy",
                "Amlodipine is extensively metabolized by the liver; titrate slowly when administering to patients with severe hepatic impairment",
                "Hydrochlorothiazide can cause hypokalemia, hyponatremia and hypomagnesemia; hypomagnesemia can result in hypokalemia which may be difficult to treat despite potassium repletion; the drug combination therapy also contains olmesartan, a drug that affects the renin angiotensin system (RAS); drugs that inhibit the RAS can also cause hyperkalemia; hydrochlorothiazide may alter glucose tolerance and raise serum levels of cholesterol and triglycerides; hydrochlorothiazide decreases urinary calcium excretion and may cause elevations of serum calcium; monitor calcium levels",
                "The recommended initial dose of amlodipine in patients 75 years of age or older is 2.5 mg, a dose not available with the drug combination therapy",
                "The recommended initial dose of amlodipine in patients with severe hepatic impairment is 2.5 mg, a dose not available with the drug combination therapy",
                "Thiazides may precipitate azotemia in patients with renal disease; cumulative effects of the drug may develop in patients with impaired renal function"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "aliskiren",
            "description": {
                "common": "olmesartan decreases effects of aliskiren by Other (see comment). Contraindicated. \nComment: Aliskiren use contraindicated with ARBs in patients with diabetes; avoid coadministration with ARBs if GFR. In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of ARBS with drugs that affect RAAS may increase the risk of renal impairment (including acute renal failure) and cause loss of antihypertensive effect. Monitor renal function periodically."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dantrolene",
            "description": {
                "common": "dantrolene, amlodipine.\nEither increases toxicity of the other by Mechanism: pharmacodynamic synergism. Contraindicated. Rare incidence of cardiovascular collapse and marked hyperkalemia observed when coadministered; may be higher risk with nondihydropyridine calcium channel blockers."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sparsentan",
            "description": {
                "common": "sparsentan, olmesartan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of ARBs with sparsentan is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (eg, acute renal failure)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid oral",
            "description": {
                "common": "aminolevulinic acid oral, hydrochlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid topical",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benazepril",
            "description": {
                "common": "olmesartan, benazepril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "captopril",
            "description": {
                "common": "olmesartan, captopril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine, hydrochlorothiazide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of systemic hyponatremia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Calcium channel blockers with depressant effects on the sinus and AV nodes could potentiate dronedarone's effects on conduction. Give a low dose of calcium channel blockers initially and increase only ECG is reviewed and tolerated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of cyclophosphamide by decreasing renal clearance. Avoid or Use Alternate Drug. Increased myelosuppressive effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine, hydrochlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of systemic hyponatremia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Concomitant use with amlodipine and diltiazem reported an a 60% increase in amlodipine AUC. Monitor increased effects and toxicities (eg, bradycardia, sinus arrest, decreased cardiac output) if amiodarone is concomitantly used with nondihydropyridine calcium channel blocker (ie, diltiazem)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dofetilide",
            "description": {
                "common": "hydrochlorothiazide increases levels of dofetilide by decreasing renal clearance. Contraindicated. Risk of prolonged QTc interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enalapril",
            "description": {
                "common": "olmesartan, enalapril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosinopril",
            "description": {
                "common": "olmesartan, fosinopril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid, hydrochlorothiazide. Other (see comment). Contraindicated. \nComment: Additive hypotensive effects may be seen when MAOI's are combined with antihypertensives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of olmesartan by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, an OATP1B1 and OATP1B3 inhibitor, may increase systemic exposure of these substrates "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisinopril",
            "description": {
                "common": "olmesartan, lisinopril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lithium",
            "description": {
                "common": "olmesartan increases toxicity of lithium by decreasing renal clearance. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofexidine",
            "description": {
                "common": "lofexidine, hydrochlorothiazide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "amlodipine will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methyl aminolevulinate",
            "description": {
                "common": "hydrochlorothiazide, methyl aminolevulinate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "moexipril",
            "description": {
                "common": "olmesartan, moexipril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perindopril",
            "description": {
                "common": "olmesartan, perindopril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "potassium phosphates, IV",
            "description": {
                "common": "olmesartan and potassium phosphates, IV both increase  serum potassium. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinapril",
            "description": {
                "common": "olmesartan, quinapril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ramipril",
            "description": {
                "common": "olmesartan, ramipril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "simvastatin",
            "description": {
                "common": "amlodipine increases levels of simvastatin by Other (see comment). Avoid or Use Alternate Drug. \nComment: Benefits of combination therapy should be carefully weighed against the potential risks of combination. Potential for increased risk of myopathy/rhabdomyolysis. Limit simvastatin dose to no more than 20 mg/day when used concurrently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "squill",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of squill by Other (see comment). Avoid or Use Alternate Drug. \nComment: Potassium depletion may enhance toxicity of squill."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trandolapril",
            "description": {
                "common": "olmesartan, trandolapril.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tretinoin",
            "description": {
                "common": "hydrochlorothiazide, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tretinoin topical",
            "description": {
                "common": "hydrochlorothiazide, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trofinetide",
            "description": {
                "common": "trofinetide will increase the level or effect of olmesartan by  Other (see comment). Avoid or Use Alternate Drug. Trofinetide (an OATP131 and OATP13B inhibitor) may increase plasma levels of OATP131 or OATP13B substrates. Avoid coadministration with sensitive substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "olmesartan and aceclofenac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "acemetacin increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "olmesartan and acemetacin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albiglutide",
            "description": {
                "common": "olmesartan increases effects of albiglutide by Other (see comment). Use Caution/Monitor. \nComment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albiglutide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of albiglutide by pharmacodynamic antagonism. Use Caution/Monitor. Thiazide diuretics can decrease insulin sensitivity thereby leading to glucose intolerance and hyperglycemia. Monitor glycemic control especially when initiating, discontinuing, or increasing thiazide diuretic dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "alfuzosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "albuterol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin increases effects of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, olmesartan.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiloride",
            "description": {
                "common": "amiloride increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of olmesartan by  increasing elimination. Use Caution/Monitor. Apalutamide weakly induces OATP1B1 and may decrease systemic exposure of drugs that are OATP1B1 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxicillin",
            "description": {
                "common": "amoxicillin, hydrochlorothiazide.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "arformoterol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "aspirin rectal increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "olmesartan, aspirin/citric acid/sodium bicarbonate.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "amlodipine will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avanafil",
            "description": {
                "common": "avanafil increases effects of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avanafil",
            "description": {
                "common": "avanafil increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avanafil",
            "description": {
                "common": "avanafil increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "amlodipine will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "amlodipine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "beclomethasone, inhaled",
            "description": {
                "common": "beclomethasone, inhaled increases toxicity of hydrochlorothiazide by increasing elimination. Use Caution/Monitor. May increase the hypokalemic effects of thiazide diuretics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "benazepril increases toxicity of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects; increased risk of nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "olmesartan increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol, amlodipine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol, amlodipine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for decreased effects of amlodipine (CYP3A4 substrate) if bosentan is initiated/dose increased. Also, monitor toxicities of amlodipine if bosentan is discontinued/dose decreased."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bretylium",
            "description": {
                "common": "hydrochlorothiazide, bretylium.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bretylium",
            "description": {
                "common": "olmesartan, bretylium.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bretylium",
            "description": {
                "common": "amlodipine, bretylium.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bumetanide",
            "description": {
                "common": "bumetanide and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection decreases effects of hydrochlorothiazide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Opioids can reduce diuretic efficacy by inducing antidiuretic hormone release."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcifediol",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of calcifediol by Other (see comment). Use Caution/Monitor. \nComment: Thiazide diuretics may increase serum calcium by decreasing urinary calcium excretion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "calcium acetate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "calcium chloride decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "calcium citrate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "calcium gluconate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "canagliflozin",
            "description": {
                "common": "olmesartan and canagliflozin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "candesartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "captopril, hydrochlorothiazide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Increased risk of nephrotoxicity. Monitor blood pressure and renal function."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbenoxolone",
            "description": {
                "common": "hydrochlorothiazide and carbenoxolone both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbidopa",
            "description": {
                "common": "carbidopa increases effects of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "carvedilol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefprozil",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of cefprozil by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "olmesartan and celecoxib both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol, amlodipine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "olmesartan and celiprolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "olmesartan increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "olmesartan increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of hydrochlorothiazide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "olmesartan and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "hydrochlorothiazide, citalopram. pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased effect of calcium channel blockers may lead to hypotension, edema, decreased HR, and acute kidney injury due to reduced renal blood flow"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clevidipine",
            "description": {
                "common": "amlodipine and clevidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colesevelam",
            "description": {
                "common": "colesevelam decreases levels of olmesartan by drug binding in GI tract. Use Caution/Monitor. Concomitant administration decreases levothyroxine absorption; however, absorption is not reduced when levothyroxine is administered 4 hr before colesevelam."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk increases effects of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypokalemia (theoretical interaction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "corticotropin",
            "description": {
                "common": "corticotropin increases toxicity of hydrochlorothiazide by increasing renal clearance. Use Caution/Monitor. May enhance hypokalemic effect of thiazide diuretics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine increases toxicity of hydrochlorothiazide by unspecified interaction mechanism. Use Caution/Monitor. Coadministration of hydrochlorothiazide with cyclosporine may increase the risk of hypermagnesemia, hyperuricemia, and possible nephrotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "hydrochlorothiazide and deflazacort both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "dalteparin increases toxicity of olmesartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazoxide",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of diazoxide by unspecified interaction mechanism. Use Caution/Monitor. May enhance hyperglycemic effects of diazoxide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "olmesartan and diclofenac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicloxacillin",
            "description": {
                "common": "dicloxacillin, hydrochlorothiazide.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "olmesartan and diflunisal both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "diflunisal increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "hydrochlorothiazide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "amlodipine and diltiazem both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dobutamine",
            "description": {
                "common": "dobutamine and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dofetilide",
            "description": {
                "common": "dofetilide will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopexamine",
            "description": {
                "common": "dopexamine and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxazosin",
            "description": {
                "common": "doxazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "drospirenone increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Calcium channel blockers with depressant effects on the sinus and AV nodes could potentiate dronedarone's effects on conduction. Give a low dose of calcium channel blockers initially and increase only ECG is reviewed and tolerated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "olmesartan and drospirenone both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "empagliflozin",
            "description": {
                "common": "empagliflozin, hydrochlorothiazide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of empagliflozin with diuretics results in increased urine volume and frequency of voids, which might enhance the potential for volume depletion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, amlodipine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "enoxaparin increases toxicity of olmesartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "ephedrine and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine",
            "description": {
                "common": "epinephrine and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "epinephrine racemic and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "eprosartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eplerenone",
            "description": {
                "common": "olmesartan, eplerenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol, amlodipine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "ethacrynic acid and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "etodolac increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "olmesartan and etodolac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "olmesartan increases effects of exenatide injectable solution by Other (see comment). Use Caution/Monitor. \nComment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "olmesartan increases effects of exenatide injectable suspension by Other (see comment). Use Caution/Monitor. \nComment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "hydrochlorothiazide decreases effects of exenatide injectable solution by pharmacodynamic antagonism. Use Caution/Monitor. Thiazide diuretics can decrease insulin sensitivity thereby leading to glucose intolerance and hyperglycemia. Monitor glycemic control especially when initiating, discontinuing, or increasing thiazide diuretic dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "hydrochlorothiazide decreases effects of exenatide injectable suspension by pharmacodynamic antagonism. Use Caution/Monitor. Thiazide diuretics can decrease insulin sensitivity thereby leading to glucose intolerance and hyperglycemia. Monitor glycemic control especially when initiating, discontinuing, or increasing thiazide diuretic dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "amlodipine and felodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenbufen",
            "description": {
                "common": "olmesartan and fenbufen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "olmesartan, fenoprofen.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "fentanyl decreases effects of hydrochlorothiazide by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "amlodipine will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "fentanyl intranasal decreases effects of hydrochlorothiazide by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "fentanyl transdermal decreases effects of hydrochlorothiazide by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "fentanyl transmucosal decreases effects of hydrochlorothiazide by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "amlodipine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "olmesartan and flurbiprofen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "formoterol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of olmesartan by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "furosemide",
            "description": {
                "common": "furosemide and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "hydrochlorothiazide and gentamicin both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir will increase the level or effect of olmesartan by  Other (see comment). Use Caution/Monitor. Coadministration with glecaprevir/pibrentasvir may increase plasma concentration of drugs that are substrates of OATP1B1 or OATP1B3"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "ibuprofen increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "griseofulvin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "heparin increases toxicity of olmesartan by Other (see comment). Use Caution/Monitor. \nComment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "olmesartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "olmesartan and ibuprofen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "olmesartan and ibuprofen IV both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone and amlodipine both increase  additive vasodilation. Use Caution/Monitor. Calcium channel blockers with iloperidone may potentiate the hypotensive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indacaterol, inhaled",
            "description": {
                "common": "hydrochlorothiazide, indacaterol, inhaled. serum potassium. Use Caution/Monitor. Combination may increase risk of hypokalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "olmesartan increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "olmesartan, indomethacin.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "olmesartan increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. \nComment: Diuretics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, possibly by diuretic-induced hpokalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "olmesartan increases effects of insulin aspart protamine/insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "olmesartan, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "olmesartan, insulin degludec/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "olmesartan increases effects of insulin detemir by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. \nComment: Diuretics may cause hyperglycemia and glycosuria in patients with diabetes mellitus, possibly by diuretic-induced hpokalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "olmesartan increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "olmesartan increases effects of insulin glulisine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "olmesartan, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "olmesartan increases effects of insulin isophane human/insulin regular human by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "olmesartan increases effects of insulin lispro by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "olmesartan increases effects of insulin lispro protamine/insulin lispro by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "olmesartan increases effects of insulin NPH by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "olmesartan increases effects of insulin regular human by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and ARBs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "irbesartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "amlodipine will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "isoproterenol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "amlodipine and isradipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of amlodipine by  Other (see comment). Modify Therapy/Monitor Closely. CCBs elicit negative inotropic effects which may be additive to those of itraconazole;  additionally, itraconazole can inhibit the metabolism of calcium channel blockers. Monitor for adverse reactions. Concomitant drug dose reduction may be necessary. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "juniper",
            "description": {
                "common": "juniper, hydrochlorothiazide. Other (see comment). Use Caution/Monitor. \nComment: Juniper may potentiate or interfere with diuretic therapy. Juniper has diuretic effects, but may cause kidney damage at large doses."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "olmesartan, ketoprofen.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "olmesartan, ketorolac.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "olmesartan and ketorolac intranasal both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "labetalol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "amlodipine will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "levalbuterol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of olmesartan by Other (see comment). Use Caution/Monitor. \nComment: Letermovir, an OATP1B1/3 inhibitor may increase plasma concentrations of coadministered OATP1B1/3 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lesinurad",
            "description": {
                "common": "lesinurad decreases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "levodopa increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lily of the valley",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. \nComment: Increased risk of cardiac toxicity due to K+ depletion."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liraglutide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of liraglutide by pharmacodynamic antagonism. Use Caution/Monitor. Thiazide diuretics can decrease insulin sensitivity thereby leading to glucose intolerance and hyperglycemia. Monitor glycemic control especially when initiating, discontinuing, or increasing thiazide diuretic dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of lithium by decreasing elimination. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "amlodipine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "lornoxicam increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "losartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone increases effects of amlodipine by Other (see comment). Use Caution/Monitor. \nComment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone increases effects of hydrochlorothiazide by Other (see comment). Use Caution/Monitor. \nComment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium supplement",
            "description": {
                "common": "magnesium supplement, amlodipine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc, olmesartan.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "meclofenamate increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "meclofenamate decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "mefenamic acid increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefloquine",
            "description": {
                "common": "mefloquine increases levels of amlodipine by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "olmesartan and mefenamic acid both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "meloxicam decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaproterenol",
            "description": {
                "common": "metaproterenol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "amlodipine decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor. Patient should be closely observed for loss of blood glucose control; when drugs are withdrawn from a patient receiving metformin, patient should be observed closely for hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methoxsalen",
            "description": {
                "common": "methoxsalen, hydrochlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "olmesartan increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "methylphenidate will decrease the level or effect of amlodipine by  pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate transdermal",
            "description": {
                "common": "methylphenidate transdermal decreases effects of hydrochlorothiazide by anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "hydrochlorothiazide and metolazone both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "olmesartan increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "olmesartan and metoprolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "amlodipine will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mometasone inhaled",
            "description": {
                "common": "mometasone inhaled increases toxicity of hydrochlorothiazide by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may increase hypokalemic effect of loop diuretics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxisylyte",
            "description": {
                "common": "moxisylyte and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "nabumetone decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin, hydrochlorothiazide.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "olmesartan and naproxen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "naproxen increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol, amlodipine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "olmesartan and nebivolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, hydrochlorothiazide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "amlodipine and nicardipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "amlodipine and nifedipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir",
            "description": {
                "common": "nirmatrelvir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce amlodipine dose by 50% during coadministration and for 3 more days after the last nirmatrelvir/ritonavir dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce amlodipine dose by 50% during coadministration and for 3 more days after the last nirmatrelvir/ritonavir dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "amlodipine and nisoldipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, amlodipine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. Observe for possible additive hypotensive effects during concomitant use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin sublingual",
            "description": {
                "common": "amlodipine, nitroglycerin sublingual.\nEither increases toxicity of the other by additive vasodilation. Modify Therapy/Monitor Closely. Marked orthostatic hypotension reported with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "norepinephrine and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "oliceridine decreases effects of hydrochlorothiazide by Other (see comment). Use Caution/Monitor. \nComment: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Monitor for signs of diminished diuresis and/or effects on blood pressure and increase dosage of the diuretic as needed. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "olmesartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olodaterol inhaled",
            "description": {
                "common": "hydrochlorothiazide and olodaterol inhaled both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "oxaprozin increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroprusside sodium",
            "description": {
                "common": "amlodipine increases effects of nitroprusside sodium by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "parecoxib increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease dose of calcium channel blocker; dose of amlodipine should be decreased by at least 50%; clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. if such events occur, consider further dose reduction of  calcium channel blocker or switching to alternative to calcium channel blocker "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "olmesartan and parecoxib both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillin G aqueous",
            "description": {
                "common": "penicillin G aqueous, hydrochlorothiazide.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "olmesartan and pindolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pirbuterol",
            "description": {
                "common": "pirbuterol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenoxybenzamine",
            "description": {
                "common": "phenoxybenzamine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentolamine",
            "description": {
                "common": "phentolamine and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "amlodipine will increase the level or effect of phenytoin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "olmesartan and piroxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pivmecillinam",
            "description": {
                "common": "pivmecillinam, hydrochlorothiazide.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "porfimer",
            "description": {
                "common": "hydrochlorothiazide, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "olmesartan and potassium acid phosphate both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium chloride",
            "description": {
                "common": "olmesartan and potassium chloride both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "potassium citrate increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium citrate/citric acid",
            "description": {
                "common": "olmesartan and potassium citrate/citric acid both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium iodide",
            "description": {
                "common": "potassium iodide and olmesartan both increase  serum potassium. Use Caution/Monitor. Potassium salts may increase the hyperkalemic effects of ARBs; the effect may be the result of aldosterone suppression in patients receiving ARBs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "prazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procainamide",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of procainamide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "olmesartan and sacubitril/valsartan both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "salicylates (non-asa) increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "olmesartan and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salmeterol",
            "description": {
                "common": "salmeterol and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "olmesartan and salsalate both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "shark cartilage",
            "description": {
                "common": "hydrochlorothiazide, shark cartilage. Other (see comment). Use Caution/Monitor. \nComment: May lead to hypercalcemia (theoretical)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "silodosin",
            "description": {
                "common": "silodosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of hydrochlorothiazide by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of olmesartan by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "hydrochlorothiazide and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "sofosbuvir/velpatasvir increases levels of olmesartan by Other (see comment). Use Caution/Monitor. \nComment: Velpatasvir inhibits OATP1B1, OATP1B3, and OATP2B1 transporters. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "olmesartan and sotalol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "spironolactone increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "olmesartan and spironolactone both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, amlodipine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "succinylcholine increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "olmesartan, sulfasalazine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "olmesartan, sulindac.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: May result in renal function deterioration, particularly in elderly or volume depleted individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "synthetic human angiotensin II",
            "description": {
                "common": "olmesartan decreases effects of synthetic human angiotensin II by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tadalafil",
            "description": {
                "common": "tadalafil increases effects of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "amlodipine will increase the level or effect of tacrolimus by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Adjust dose when appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tadalafil",
            "description": {
                "common": "tadalafil increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "telmisartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temocillin",
            "description": {
                "common": "temocillin, hydrochlorothiazide.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbutaline",
            "description": {
                "common": "olmesartan increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticarcillin",
            "description": {
                "common": "ticarcillin, hydrochlorothiazide.\nEither increases levels of the other by decreasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "amlodipine increases toxicity of temsirolimus by Other (see comment). Use Caution/Monitor. \nComment: Combination of mTOR inhibitors with calcium channel blockers increases risk of angioedema."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terazosin",
            "description": {
                "common": "terazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "timolol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "amlodipine will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "tolfenamic acid increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tizanidine",
            "description": {
                "common": "tizanidine increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "olmesartan and tolfenamic acid both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "olmesartan and tolmetin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "olmesartan and tolvaptan both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "toremifene",
            "description": {
                "common": "hydrochlorothiazide, toremifene. Other (see comment). Use Caution/Monitor. \nComment: Thiazide diuretics decrease renal calcium excretion and may increase risk of hypercalcemia in patients taking toremifene."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "olmesartan increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "torsemide and hydrochlorothiazide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "treprostinil",
            "description": {
                "common": "treprostinil increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamterene",
            "description": {
                "common": "olmesartan and triamterene both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trientine",
            "description": {
                "common": "hydrochlorothiazide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimagnesium citrate anhydrous",
            "description": {
                "common": "trimagnesium citrate anhydrous, amlodipine.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "trimethoprim and olmesartan both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "umeclidinium bromide/vilanterol inhaled and hydrochlorothiazide both decrease  serum potassium. Modify Therapy/Monitor Closely. Electrocardiographic changes and/or hypokalemia associated with non?potassium-sparing diuretics may worsen with concomitant beta-agonists, particularly if recommended dose is exceeded"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "valsartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "amlodipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "vilanterol/fluticasone furoate inhaled and hydrochlorothiazide both decrease  serum potassium. Modify Therapy/Monitor Closely. Beta-agonists may acutely worsen ECG changes and/or hypokalemia resulting from non-potassium-sparing diuretics "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vitamin D",
            "description": {
                "common": "hydrochlorothiazide increases effects of vitamin D by Other (see comment). Use Caution/Monitor. \nComment: Combination may increase hypercalcemic effect of vitamin D analogs. Use with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin and olmesartan both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "xipamide",
            "description": {
                "common": "xipamide increases effects of hydrochlorothiazide by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acarbose",
            "description": {
                "common": "hydrochlorothiazide decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of aceclofenac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acemetacin",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of acemetacin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acyclovir",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of acyclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "agrimony",
            "description": {
                "common": "agrimony increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "albuterol",
            "description": {
                "common": "albuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aminohippurate sodium",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of aminohippurate sodium by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ampicillin",
            "description": {
                "common": "hydrochlorothiazide increases levels of ampicillin by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "arformoterol",
            "description": {
                "common": "arformoterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of aspirin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of aspirin rectal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of aspirin/citric acid/sodium bicarbonate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "balsalazide",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of balsalazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "birch",
            "description": {
                "common": "birch increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bitter melon",
            "description": {
                "common": "bitter melon, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcitriol topical",
            "description": {
                "common": "calcitriol topical, hydrochlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "hydrochlorothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "hydrochlorothiazide increases levels of calcium carbonate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "hydrochlorothiazide increases levels of calcium chloride by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "hydrochlorothiazide increases levels of calcium citrate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "hydrochlorothiazide increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbenoxolone",
            "description": {
                "common": "hydrochlorothiazide, carbenoxolone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypokalemic effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefadroxil",
            "description": {
                "common": "cefadroxil will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefamandole",
            "description": {
                "common": "cefamandole will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefpirome",
            "description": {
                "common": "cefpirome will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cefprozil",
            "description": {
                "common": "cefprozil will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ceftibuten",
            "description": {
                "common": "ceftibuten will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celecoxib",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of celecoxib by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cephalexin",
            "description": {
                "common": "cephalexin will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of chlorpropamide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol decreases levels of hydrochlorothiazide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk increases effects of olmesartan by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aprepitant",
            "description": {
                "common": "aprepitant will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atracurium",
            "description": {
                "common": "amlodipine increases effects of atracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "amlodipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cosyntropin",
            "description": {
                "common": "cosyntropin, hydrochlorothiazide. pharmacodynamic synergism. Minor/Significance Unknown. Possible enhanced electrolyte loss."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dasatinib",
            "description": {
                "common": "dasatinib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "DHEA, herbal",
            "description": {
                "common": "DHEA, herbal will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazoxide",
            "description": {
                "common": "diazoxide, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hyperglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diclofenac",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of diclofenac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diflunisal",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of diflunisal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dobutamine",
            "description": {
                "common": "dobutamine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dopexamine",
            "description": {
                "common": "dopexamine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "entecavir",
            "description": {
                "common": "olmesartan, entecavir.\nEither increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ephedrine",
            "description": {
                "common": "ephedrine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "epinephrine",
            "description": {
                "common": "epinephrine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "epinephrine racemic, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "epoprostenol",
            "description": {
                "common": "epoprostenol increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etodolac",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of etodolac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenbufen",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of fenbufen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of fenoprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of flurbiprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fo-ti",
            "description": {
                "common": "fo-ti increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "folic acid",
            "description": {
                "common": "hydrochlorothiazide decreases levels of folic acid by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "forskolin",
            "description": {
                "common": "forskolin increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "formoterol",
            "description": {
                "common": "formoterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "forskolin",
            "description": {
                "common": "forskolin increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "fosaprepitant will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of ganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glimepiride",
            "description": {
                "common": "hydrochlorothiazide decreases effects of glimepiride by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glipizide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of glipizide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of glyburide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "goldenrod",
            "description": {
                "common": "goldenrod increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of ibuprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "incobotulinumtoxinA",
            "description": {
                "common": "amlodipine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of indapamide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indomethacin",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of indomethacin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin detemir by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin glulisine by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin lispro by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin NPH by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "hydrochlorothiazide decreases effects of insulin regular human by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "isoproterenol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of ketoprofen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketorolac",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of ketorolac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of ketorolac intranasal by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "L-methylfolate",
            "description": {
                "common": "hydrochlorothiazide decreases levels of L-methylfolate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "levalbuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lithium",
            "description": {
                "common": "amlodipine increases toxicity of lithium by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of neurotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of lornoxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium chloride",
            "description": {
                "common": "hydrochlorothiazide decreases levels of magnesium chloride by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium citrate",
            "description": {
                "common": "hydrochlorothiazide decreases levels of magnesium citrate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "hydrochlorothiazide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "hydrochlorothiazide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "hydrochlorothiazide decreases levels of magnesium sulfate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of meclofenamate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of mefenamic acid by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meloxicam",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of meloxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "memantine",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mesalamine",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of mesalamine by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metaproterenol",
            "description": {
                "common": "metaproterenol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metformin",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methotrexate",
            "description": {
                "common": "hydrochlorothiazide increases toxicity of methotrexate by decreasing elimination. Minor/Significance Unknown. Increased myelosuppression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metipranolol ophthalmic",
            "description": {
                "common": "metipranolol ophthalmic increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of metolazone by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "midodrine",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of midodrine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "miglitol",
            "description": {
                "common": "hydrochlorothiazide decreases effects of miglitol by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "minoxidil",
            "description": {
                "common": "hydrochlorothiazide increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nabumetone",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of nabumetone by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "naproxen",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of naproxen by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nateglinide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of nateglinide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "noni juice",
            "description": {
                "common": "noni juice increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "norepinephrine, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "octacosanol",
            "description": {
                "common": "octacosanol increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "octacosanol",
            "description": {
                "common": "octacosanol increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of ofloxacin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "amlodipine increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of oxaprozin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "parecoxib",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of parecoxib by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "patiromer",
            "description": {
                "common": "patiromer, olmesartan. cation binding in GI tract. Minor/Significance Unknown. No observed clinically important interaction. No separation of dosing required."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pancuronium",
            "description": {
                "common": "amlodipine increases effects of pancuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "penicillin G aqueous",
            "description": {
                "common": "hydrochlorothiazide increases levels of penicillin G aqueous by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "penicillin VK",
            "description": {
                "common": "hydrochlorothiazide increases levels of penicillin VK by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "hydrochlorothiazide decreases effects of pioglitazone by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "piperacillin",
            "description": {
                "common": "hydrochlorothiazide increases levels of piperacillin by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pirbuterol",
            "description": {
                "common": "pirbuterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "piroxicam",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of piroxicam by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "porfimer",
            "description": {
                "common": "amlodipine decreases levels of porfimer by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinine",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of quinine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinupristin/dalfopristin",
            "description": {
                "common": "quinupristin/dalfopristin will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "amlodipine increases effects of rapacuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "reishi",
            "description": {
                "common": "reishi increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "repaglinide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of repaglinide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rocuronium",
            "description": {
                "common": "amlodipine increases effects of rocuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "rose hips will increase the level or effect of hydrochlorothiazide by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "hydrochlorothiazide decreases effects of rosiglitazone by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of salicylates (non-asa) by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "salmeterol",
            "description": {
                "common": "salmeterol, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "salsalate",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of salsalate by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "hydrochlorothiazide decreases effects of saxagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shepherd's purse",
            "description": {
                "common": "shepherd's purse, hydrochlorothiazide. Other (see comment). Minor/Significance Unknown. \nComment: Theoretically, shepherd's purse may interfere with BP control."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "hydrochlorothiazide decreases effects of sitagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "amlodipine will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "amlodipine will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shepherd's purse",
            "description": {
                "common": "shepherd's purse, amlodipine. Other (see comment). Minor/Significance Unknown. \nComment: Theoretically, shepherd's purse may interfere with BP control."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "amlodipine increases effects of succinylcholine by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "hydrochlorothiazide increases levels of sulfadiazine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of sulfasalazine by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "hydrochlorothiazide increases levels of sulfisoxazole by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulindac",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of sulindac by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "terbutaline",
            "description": {
                "common": "terbutaline, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tizanidine",
            "description": {
                "common": "tizanidine increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolazamide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "treprostinil",
            "description": {
                "common": "treprostinil increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "hydrochlorothiazide decreases effects of tolbutamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of tolfenamic acid by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolmetin",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of tolmetin by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "treprostinil",
            "description": {
                "common": "treprostinil increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamterene",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trilostane",
            "description": {
                "common": "trilostane, hydrochlorothiazide. Other (see comment). Minor/Significance Unknown. \nComment: Trilostane reduces K+ loss while maintaining the natriuretic effect.  Mechanism:  inhibition of mineralocorticoid steroid synthesis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valganciclovir",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of valganciclovir by  acidic (anionic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vecuronium",
            "description": {
                "common": "amlodipine increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "hydrochlorothiazide will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verteporfin",
            "description": {
                "common": "hydrochlorothiazide, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vildagliptin",
            "description": {
                "common": "hydrochlorothiazide decreases effects of vildagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin will increase the level or effect of olmesartan by  Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Non",
            "percent": null
        },
        {
            "name": "melanoma skin cancer",
            "percent": null
        }
    ]
}